Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

NeoGenomics, Inc. - Common Stock (NQ:NEO)

9.890 -0.120 (-1.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE
News headline image
NeoGenomics Reports Third Quarter 2023 Results
Via ACCESSWIRE
News headline image
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Via ACCESSWIRE
News headline image
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
Via ACCESSWIRE
News headline image
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
NeoGenomics Reports Second Quarter 2023 Results
Via ACCESSWIRE
News headline image
NeoGenomics Reports First Quarter 2023 Results
Via ACCESSWIRE
News headline image
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Via ACCESSWIRE
News headline image
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Via ACCESSWIRE
News headline image
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Via ACCESSWIRE
News headline image
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Via ACCESSWIRE
News headline image
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Via ACCESSWIRE
News headline image
NeoGenomics Reports Fourth Quarter and Full Year 2022 Results
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Via ACCESSWIRE
News headline image
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
Via ACCESSWIRE
News headline image
NeoGenomics, Inc. (NASDAQ:NEO) Long Term Investor Alert: Investigation of Potential Wrongdoing ↗
San Diego, CA -- (SBWIRE) -- 04/20/2023 -- An investigation concerning potential breaches of fiduciary duties by certain directors and officers of NeoGenomics, Inc was announced. 
Via SBWire
News headline image
NeoGenomics to Announce First Quarter 2023 Financial Results
Via ACCESSWIRE
News headline image
NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
News headline image
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
Via ACCESSWIRE
News headline image
NeoGenomics to Host Investor Day on April 4, 2023
Via ACCESSWIRE
News headline image
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
From Massive Bio, Inc.
Via Business Wire
News headline image
NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
Via ACCESSWIRE
News headline image
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
Via ACCESSWIRE
News headline image
NeoGenomics to Present at the 44th Annual Raymond James Institutional Investors Conference
Via ACCESSWIRE
News headline image
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of NeoGenomics Laboratories, Inc. (NEO) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
NeoGenomics, Inc. (NASDAQ:NEO) Investor Notice: Deadline in Lawsuit on February 6, 2023 ↗
San Diego, CA -- (SBWIRE) -- 02/06/2023 -- The Shareholders Foundation announced that a deadline is coming up on February 6, 2023 in the lawsuit filed for certain investors of NeoGenomics, Inc.... 
Via SBWire
News headline image
NEO FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages NeoGenomics, Inc. Investors to Secure Counsel Before Important February 6 Deadline in Securities Class Action - NEO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NeoGenomics, Inc. (NEO) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.